-
1
-
-
0024561852
-
Tamoxifen and the uterus and endometrium
-
10.1016/S0140-6736(89)91741-8
-
P Neven X De Muylder Y Van Belle et al. 1989 Tamoxifen and the uterus and endometrium Lancet 1 375 10.1016/S0140-6736(89)91741-8
-
(1989)
Lancet
, vol.1
, pp. 375
-
-
Neven, P.1
De Muylder, X.2
Van Belle, Y.3
-
2
-
-
0026408075
-
Effects of tamoxifen on the female genital tract
-
10.1111/j.1749-6632.1991.tb37890.x
-
T Fornander LE Rutquivist N Wilking 1991 Effects of tamoxifen on the female genital tract Ann N Y Acad Sci 622 469 476 10.1111/j.1749-6632.1991. tb37890.x
-
(1991)
Ann N Y Acad Sci
, vol.622
, pp. 469-476
-
-
Fornander, T.1
Rutquivist, L.E.2
Wilking, N.3
-
3
-
-
0028287647
-
Effects of tamoxifen on the uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
-
10.1016/S0140-6736(94)92466-X
-
RP Kedar TH Bourne TJ Powles et al. 1994 Effects of tamoxifen on the uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial Lancet 343 1318 1321 10.1016/S0140-6736(94)92466-X
-
(1994)
Lancet
, vol.343
, pp. 1318-1321
-
-
Kedar, R.P.1
Bourne, T.H.2
Powles, T.J.3
-
4
-
-
0032537990
-
Tamoxifen for prevention of breast cancer. Report of the national surgical adjuvant breast and bowel project P-1 study
-
10.1093/jnci/90.18.1371
-
B Fisher JP Constantino DL Wickerham et al. 1998 Tamoxifen for prevention of breast cancer. Report of the national surgical adjuvant breast and bowel project P-1 study J Natl Cancer Inst 90 1371 1388 10.1093/jnci/90.18.1371
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1371-1388
-
-
Fisher, B.1
Constantino, J.P.2
Wickerham, D.L.3
-
5
-
-
27644458191
-
Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting
-
10.1097/01.cco.0000180434.31991.bf
-
L Morales P Neven R Paridaens 2005 Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting Curr Opin Oncol 17 559 565 10.1097/01.cco.0000180434.31991.bf
-
(2005)
Curr Opin Oncol
, vol.17
, pp. 559-565
-
-
Morales, L.1
Neven, P.2
Paridaens, R.3
-
6
-
-
34848866584
-
The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: Evidence based review
-
R Poole R Paridaens 2007 The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review Curr Opin Oncol 19 564 572
-
(2007)
Curr Opin Oncol
, vol.19
, pp. 564-572
-
-
Poole, R.1
Paridaens, R.2
-
7
-
-
33846179352
-
Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations
-
10.1016/j.ejca.2006.09.003
-
B Thuerlimann D Koeberle HJ Senn 2007 Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations Eur J Cancer 43 46 52 10.1016/j.ejca.2006. 09.003
-
(2007)
Eur J Cancer
, vol.43
, pp. 46-52
-
-
Thuerlimann, B.1
Koeberle, D.2
Senn, H.J.3
-
8
-
-
19944429637
-
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients
-
10.1093/annonc/mdi021
-
L Morales D Timmerman P Neven et al. 2005 Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients Ann Oncol 16 70 74 10.1093/annonc/mdi021
-
(2005)
Ann Oncol
, vol.16
, pp. 70-74
-
-
Morales, L.1
Timmerman, D.2
Neven, P.3
-
9
-
-
27644547479
-
Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients: A prospective TVUS study
-
O Garrone S Mezi M Occelli 2003 Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients: a prospective TVUS study Ann Oncol 14 s22
-
(2003)
Ann Oncol
, vol.14
, pp. 22
-
-
Garrone, O.1
Mezi, S.2
Occelli, M.3
-
10
-
-
31544474866
-
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment
-
10.1093/humrep/dei322
-
S Duffy TL Jackson M Lansdown et al. 2006 The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment Hum Reprod 21 545 553 10.1093/humrep/dei322
-
(2006)
Hum Reprod
, vol.21
, pp. 545-553
-
-
Duffy, S.1
Jackson, T.L.2
Lansdown, M.3
-
11
-
-
33644775724
-
Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology
-
10.1158/1078-0432.CCR-05-0225
-
B Gerber A Krause T Reimer et al. 2006 Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology Clin Cancer Res 12 1245 1250 10.1158/1078-0432.CCR-05-0225
-
(2006)
Clin Cancer Res
, vol.12
, pp. 1245-1250
-
-
Gerber, B.1
Krause, A.2
Reimer, T.3
-
12
-
-
33750192472
-
Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors
-
10.1016/j.ygyno.2006.04.004
-
G Garuti F Cellani G Centinaio et al. 2006 Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors Gynecol Oncol 103 599 603 10.1016/j.ygyno.2006.04.004
-
(2006)
Gynecol Oncol
, vol.103
, pp. 599-603
-
-
Garuti, G.1
Cellani, F.2
Centinaio, G.3
-
13
-
-
33846294351
-
Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients
-
10.1007/s10549-006-9285-x
-
O Markovitch R Tepper A Fishman et al. 2007 Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients Breast Cancer Res Treat 101 185 190 10.1007/s10549-006-9285-x
-
(2007)
Breast Cancer Res Treat
, vol.101
, pp. 185-190
-
-
Markovitch, O.1
Tepper, R.2
Fishman, A.3
-
14
-
-
69049095818
-
Endometrial status in the Intergroup Exemestane Study (IES) up to 2 years post-treatment
-
G Bertelli E Hall E Ireland et al. 2007 Endometrial status in the Intergroup Exemestane Study (IES) up to 2 years post-treatment Breast Cancer Res Treat 106 s111
-
(2007)
Breast Cancer Res Treat
, vol.106
, pp. 111
-
-
Bertelli, G.1
Hall, E.2
Ireland, E.3
-
15
-
-
69049091679
-
Endometrial safety of cross-over treatment with tamoxifen followed by exemestane
-
DG Kieback N Harbeck W Bauer et al. 2008 Endometrial safety of cross-over treatment with tamoxifen followed by exemestane Eur J Cancer 6 s198
-
(2008)
Eur J Cancer
, vol.6
, pp. 198
-
-
Kieback, D.G.1
Harbeck, N.2
Bauer, W.3
-
16
-
-
39749201478
-
From endometrial hyperplasia to endometrial cancer: Insight into the biology and possible medical preventive measures
-
MC Boruban K Altundag GS Kilic J Blankstein 2008 From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures Eur J Cancer Prev 17 133 138
-
(2008)
Eur J Cancer Prev
, vol.17
, pp. 133-138
-
-
Boruban, M.C.1
Altundag, K.2
Kilic, G.S.3
Blankstein, J.4
-
17
-
-
0035718191
-
Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer
-
10.1016/S0960-0760(01)00138-8
-
JFR Robertson 2001 Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer J Steroid Biochem Mol Biol 79 209 212 10.1016/S0960-0760(01)00138-8
-
(2001)
J Steroid Biochem Mol Biol
, vol.79
, pp. 209-212
-
-
Robertson, J.F.R.1
-
18
-
-
22244449598
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma
-
10.1002/cncr.21163
-
A Howell J Pippen RM Elledge et al. 2005 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma Cancer 104 236 239 10.1002/cncr.21163
-
(2005)
Cancer
, vol.104
, pp. 236-239
-
-
Howell, A.1
Pippen, J.2
Elledge, R.M.3
-
19
-
-
33846543806
-
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
-
10.1093/annonc/mdl341
-
L Perey R Paridaens H Hawle et al. 2007 Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) Ann Oncol 18 64 69 10.1093/annonc/mdl341
-
(2007)
Ann Oncol
, vol.18
, pp. 64-69
-
-
Perey, L.1
Paridaens, R.2
Hawle, H.3
-
20
-
-
42149089313
-
Fulvestrant (Faslodex) in advanced breast cancer: Clinical experience from a Belgian cooperative study
-
10.1007/s10549-007-9628-2
-
P Neven R Paridaens G Pelgrims et al. 2008 Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study Breast Cancer Res Treat 109 59 65 10.1007/s10549-007-9628-2
-
(2008)
Breast Cancer Res Treat
, vol.109
, pp. 59-65
-
-
Neven, P.1
Paridaens, R.2
Pelgrims, G.3
-
21
-
-
13244290109
-
Endocrine treatment options for advanced breast cancer-the role of fulvestrant
-
10.1016/j.ejca.2004.07.035
-
JF Robertson SE Come SE Jones et al. 2005 Endocrine treatment options for advanced breast cancer-the role of fulvestrant Eur J Cancer 41 346 356 10.1016/j.ejca.2004.07.035
-
(2005)
Eur J Cancer
, vol.41
, pp. 346-356
-
-
Robertson, J.F.1
Come, S.E.2
Jones, S.E.3
-
22
-
-
43249130208
-
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
-
10.1200/JCO.2007.13.5822
-
S Chia W Gradishar L Mauriac et al. 2008 Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 1664 1670 10.1200/JCO.2007.13.5822
-
(2008)
J Clin Oncol
, vol.26
, pp. 1664-1670
-
-
Chia, S.1
Gradishar, W.2
Mauriac, L.3
-
23
-
-
16644374043
-
Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body
-
A Gaducci S Cosio AR Genazzani 2004 Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body Curr Opin Investig Drugs 5 1031 1044
-
(2004)
Curr Opin Investig Drugs
, vol.5
, pp. 1031-1044
-
-
Gaducci, A.1
Cosio, S.2
Genazzani, A.R.3
-
24
-
-
0037011660
-
A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers
-
10.1038/sj.bjc.6600644
-
S Addo RA Yates A Laight 2002 A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers Br J Cancer 87 1354 1359 10.1038/sj.bjc. 6600644
-
(2002)
Br J Cancer
, vol.87
, pp. 1354-1359
-
-
Addo, S.1
Yates, R.A.2
Laight, A.3
-
25
-
-
0037835462
-
A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy
-
10.1016/S0015-0282(03)00261-9
-
J Donnez BH Vivancos M Kudela et al. 2003 A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy Fertil Steril 79 1380 1389 10.1016/S0015-0282(03)00261-9
-
(2003)
Fertil Steril
, vol.79
, pp. 1380-1389
-
-
Donnez, J.1
Vivancos, B.H.2
Kudela, M.3
-
26
-
-
33845799161
-
Fulvestrant: A further treatment option for patients with metastatic uterine cancer?
-
10.1159/000096541
-
M Lux E Wenkel K Beckmann et al. 2006 Fulvestrant: a further treatment option for patients with metastatic uterine cancer? Onkologie 29 577 580 10.1159/000096541
-
(2006)
Onkologie
, vol.29
, pp. 577-580
-
-
Lux, M.1
Wenkel, E.2
Beckmann, K.3
-
27
-
-
30444432701
-
Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy
-
10.1016/j.ygyno.2005.09.011
-
MA Hoffman A Khan 2006 Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy Gynecol Oncol 100 439 441 10.1016/j.ygyno.2005.09.011
-
(2006)
Gynecol Oncol
, vol.100
, pp. 439-441
-
-
Hoffman, M.A.1
Khan, A.2
-
29
-
-
0032539466
-
Should tamoxifen users be screened for endometrial lesions?
-
10.1016/S0140-6736(05)78216-7
-
P Neven I Vergote 1998 Should tamoxifen users be screened for endometrial lesions? Lancet 351 155 157 10.1016/S0140-6736(05)78216-7
-
(1998)
Lancet
, vol.351
, pp. 155-157
-
-
Neven, P.1
Vergote, I.2
-
30
-
-
0036754549
-
Endometrial evaluation is a very important tool in the management of breast cancer patients
-
10.1016/S0959-8049(02)00292-7
-
M Berlière C Galant A Charles et al. 2002 Endometrial evaluation is a very important tool in the management of breast cancer patients Eur J Cancer 38 suppl. 6 67 68 10.1016/S0959-8049(02)00292-7
-
(2002)
Eur J Cancer
, vol.38
, Issue.SUPPL. 6
, pp. 67-68
-
-
Berlière, M.1
Galant, C.2
Charles, A.3
-
31
-
-
33749331845
-
Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology
-
10.1158/1078-0432.CCR-06-0897
-
L Morales R Paridaens D Timmerman P Neven 2006 Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology Clin Cancer Res 12 5603 10.1158/1078-0432.CCR-06-0897
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5603
-
-
Morales, L.1
Paridaens, R.2
Timmerman, D.3
Neven, P.4
|